BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 6089232)

  • 1. Pathogenesis of myelofibrosis: role of ineffective megakaryopoiesis and megakaryocyte components.
    Castro-Malaspina H
    Prog Clin Biol Res; 1984; 154():427-54. PubMed ID: 6089232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiological mechanisms operating in the development of myelofibrosis: role of megakaryocytes.
    Castro-Malaspina H; Moore MA
    Nouv Rev Fr Hematol (1978); 1982; 24(4):221-6. PubMed ID: 6292827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Megakaryopoiesis and myelofibrosis in chronic myeloid leukemia after allogeneic bone marrow transplantation: an immunohistochemical study of 127 patients.
    Thiele J; Kvasnicka HM; Beelen DW; Flucke U; Spoer C; Paperno S; Leder LD; Schaefer UW
    Mod Pathol; 2001 Feb; 14(2):129-38. PubMed ID: 11235904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrastructure of bone marrow tissue in so-called primary (idiopathic) myelofibrosis-osteomyelosclerosis (agnogenic myeloid metaplasia). I. Abnormalities of megakaryopoiesis and thrombocytes.
    Thiele J; Kuemmel T; Sander C; Fischer R
    J Submicrosc Cytol Pathol; 1991 Jan; 23(1):93-107. PubMed ID: 2036630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histo- and immunomorphometry of megakaryopoiesis in chronic myeloid leukemia with myelofibrosis and so-called primary (idiopathic) osteo-myelofibrosis/-sclerosis.
    Thiele J; Steinberg T; Hoeppner B; Wienhold S; Wagner S; Dienemann D; Fischer R
    Anal Cell Pathol; 1990 Jul; 2(4):215-27. PubMed ID: 2275869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current views on the pathogenesis and treatment of spontaneous (primary) myelofibrosis].
    Robak T
    Pol Tyg Lek; 1992 Feb 3-10; 47(5-6):144-7. PubMed ID: 1437804
    [No Abstract]   [Full Text] [Related]  

  • 7. Properties of myelofibrosis-derived fibroblasts.
    Castro-Malaspina H; Jhanwar SC
    Prog Clin Biol Res; 1984; 154():307-22. PubMed ID: 6382300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.
    Wang JC; Chang TH; Goldberg A; Novetsky AD; Lichter S; Lipton J
    Exp Hematol; 2006 Dec; 34(12):1617-23. PubMed ID: 17157157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphonuclear neutrophil and megakaryocyte mutual involvement in myelofibrosis pathogenesis.
    Schmitt A; Drouin A; Massé JM; Guichard J; Shagraoui H; Cramer EM
    Leuk Lymphoma; 2002 Apr; 43(4):719-24. PubMed ID: 12153156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis.
    Erba BG; Gruppi C; Corada M; Pisati F; Rosti V; Bartalucci N; Villeval JL; Vannucchi AM; Barosi G; Balduini A; Dejana E
    Am J Pathol; 2017 Aug; 187(8):1879-1892. PubMed ID: 28728747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Megakaryocytes and myelofibrosis in gray platelet syndrome.
    Caen JP; Deschamps JF; Bodevin E; Bryckaert MC; Dupuy E; Wasteson A
    Nouv Rev Fr Hematol (1978); 1987; 29(2):109-14. PubMed ID: 3615193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Myelofibrosis and the supporting fibrillary network of the hemopoietic bone marrow].
    Diebold J
    Sem Hop; 1974 May; 50(24):1619-24. PubMed ID: 4373831
    [No Abstract]   [Full Text] [Related]  

  • 13. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis.
    Thiele J; Kvasnicka HM; Zankovich R; Diehl V
    Haematologica; 2000 Nov; 85(11):1126-34. PubMed ID: 11064463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of non-canonical TGF-β1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis.
    Ciaffoni F; Cassella E; Varricchio L; Massa M; Barosi G; Migliaccio AR
    Blood Cells Mol Dis; 2015 Mar; 54(3):234-41. PubMed ID: 25703685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of myelofibrosis with myeloid metaplasia: Insight from mouse models.
    Chagraoui H; Wendling F; Vainchenker W
    Best Pract Res Clin Haematol; 2006; 19(3):399-412. PubMed ID: 16781480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mechanism of myelofibrosis in chronic myeloproliferative disorders].
    Nagao T; Yonekura S
    Rinsho Ketsueki; 1988 Jul; 29(7):983-8. PubMed ID: 2846914
    [No Abstract]   [Full Text] [Related]  

  • 17. Apoptosis (programmed cell death) in idiopathic (primary) osteo-/myelofibrosis: naked nuclei in megakaryopoiesis reveal features of para-apoptosis.
    Thiele J; Lorenzen J; Manich B; Kvasnicka HM; Zirbes TK; Fischer R
    Acta Haematol; 1997; 97(3):137-43. PubMed ID: 9066708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of megakaryocyte proliferation of the evolution of myelofibrosis. Histological follow-up study in 186 patients with chronic myeloid leukaemia.
    Buhr T; Choritz H; Georgii A
    Virchows Arch A Pathol Anat Histopathol; 1992; 420(6):473-8. PubMed ID: 1609507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypothesis: a possible role for interferon in the treatment of idiopathic myelofibrosis.
    Hasselbalch H
    Med Hypotheses; 1988 Dec; 27(4):345-7. PubMed ID: 3226365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Beneficial effect of 1,25-dihydroxyvitamin D3 in the treatment of myelofibrosis].
    Palomera L; García Díez I; Martínez R
    Med Clin (Barc); 1989 Sep; 93(7):265-8. PubMed ID: 2811498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.